Skip to main content
SpringerLink
Log in
Book cover

Drug Resistance in Leukemia and Lymphoma III pp 415–421Cite as

Cellular Drug Resistance in Childhood Acute Myeloid Leukemia

A Mini-Review with Emphasis on Cell Culture Assays

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 457))

Abstract

Cellular drug resistance is an important limiting factor in the success of chemotherapy in childhood acute myeloid leukemia (AML). We summarize the results of the studies published sofar that have focussed on drug resistance in childhood AML, using cell culture assays. We also briefly report our own results of an ongoing study. Finally, potential applications of cellular drug resistance testing are discussed. It appears that cellular drug resistance differs between AML and acute lymphoblastic leukemia and between subgroups of AML patients, that AML cells of relapsed patients are more resistant to cytarabine than those of untreated patients, and that in vitro resistance to cytarabine and daunorubicin is related to a worse prognosis. However, more and larger studies are required to determine the exact role of cellular drug resistance testing in the treatment of childhood AML.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Creutzig U, Rittter J, Schellong G. Identification of two risk groups in childhood acute myelogeneous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990, 75:1932–1940

    PubMed  CAS  Google Scholar 

  2. Pui Ch. Childhood leukemias. New Engl J Med 1995, 332:1618–1630

    Article  PubMed  CAS  Google Scholar 

  3. Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leakemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myedloid leukaemia: results of the United Kingdom Medical research Council’s 10th AML trial. Br J Haematol 1998, 101:130–140

    Article  PubMed  CAS  Google Scholar 

  4. Pieters R, Kaspers GJL, Veerman AJP. Drug sensitivity culture assays in childhood leukemia: A review of the results and applications. Int J Pediatr Hematol Oncol 1997, 4:531–541

    Google Scholar 

  5. Preisler HD, Gopal V. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 1994, 18:149–160

    Article  PubMed  CAS  Google Scholar 

  6. Bosanquet AG. Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test results with both patient response and survival. Trends in Experimental and Clinical Medicine 1994, 4:179–195

    Google Scholar 

  7. Veerman AJP, Pieters R. Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 1990, 74:381–384

    Article  PubMed  CAS  Google Scholar 

  8. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treatm Rep 1986, 70:1283–1295

    CAS  Google Scholar 

  9. Kaspers GJL, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, De Waal FC, Van Wering ER, Veerman AJP. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A preliminary report. Leukemia 1994, 8:1224–1229

    PubMed  CAS  Google Scholar 

  10. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991, 78:1125–1131

    PubMed  CAS  Google Scholar 

  11. Hongo T, Fujii Y, Yajima S. In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed chemotherapy. In: Kaspers et al. (eds). Drug Resistance in Leukemia and Lymphoma I. Harwood, 1993:313–319

    Google Scholar 

  12. Klumper E, Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Rottier MMA, Van Wering ER, Van Der Does-Van Den Berg A, Hählen K, Creutzig U, Veerman AJP. In vitro chemosensitivity testing in childhood acute non-lymphoblastic leukemia using the MTT assay. Leukemia 1995, 9:1864–1869

    PubMed  CAS  Google Scholar 

  13. Zwaan CM, Kaspers GJL, Rottier MMA, Wünsche R, Hählen K, Creuztig U, Pieters R, Veerman AJP. Circumvention of ARA-C resistance in childhood acute non-lymphoblastic leukemia (ANLL) by the use of 2-chloro-deoxyadenosine: an in vitro study. Med Pediatr Oncol 1998, 31: 230 (abstract 0-144)

    Google Scholar 

  14. Kaspers GJL, Zwaan ChM, Creutzig U, Ritter J, Rottier MMA, Pieters R, Veerman AJP. In vitro drug resistance in childhood acute myeloid leukemia: A preliminary analysis. In: Hiddemann et al. (eds). Acute Leukemias VII. Springer-Verlag, 1998:491–495

    Google Scholar 

  15. Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE. Myeloperoxydase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood 1993, 81:482–489

    PubMed  CAS  Google Scholar 

  16. Schlaifer D, Meyer K, Muller C, Attal M, Smith MT, Tamaki S, Weimels J, Pris J, Jaffrezou JP, Laurent G, et al. Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. Leukemia 1994, 8:289–291

    PubMed  CAS  Google Scholar 

  17. Dübbers A, Schulze-Westhoff P, Kurzknabe E, Creutzig U, Ritter J, Boos J. Asparagine-synthetase in paediatric acute leukemias: AML-M5-subtype shows lowest activity. Ann Hematol 1997, 74(suppl I): A37 (abstract #148)

    Google Scholar 

  18. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res 1997, 21:45–50

    Article  PubMed  CAS  Google Scholar 

  19. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells — a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996, 87:3395–3403

    PubMed  CAS  Google Scholar 

  20. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 1997, 11:1594–1595 [letter]

    Article  PubMed  CAS  Google Scholar 

  21. Zwaan CM, Ramakers-Van Woerden NL, Kaspers GJL, Pieters R, Wünsche R, Rottier MMA, Hählen K, Janka-Schaub G, Creutzig U, Veerman AJP. Favourable drug resistance profiles in children with Down’s syndrome (DS) and acute leukemia. Br J Haematol 1998, 102: 226 (poster 904)

    Google Scholar 

  22. Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB, Roberson PK. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 1986, 68:400–405

    PubMed  CAS  Google Scholar 

  23. Smith PJ, Lihou MG. Prediction of remission induction in childhood acute myeloid leukemia. Aust N Z J Med 1986, 16:39–42

    Article  PubMed  CAS  Google Scholar 

  24. Rosanda C, Garaventa A, Pasino M, Strigini P, De Bernardi B. A short-term in vitro drug sensitivity assay in pediatric malignancies. Anticancer Res 1987, 7:365–368

    PubMed  CAS  Google Scholar 

  25. Pieters R, Huismans DR, Loonen AH, Hählen K, Van der Does-van den Berg A, Van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991, 338:399–403

    Article  PubMed  CAS  Google Scholar 

  26. Kaspers GJL, AJP Veerman, R Pieters, Van Zantwijk CH, LA Smets, ER Van Wering, A Van Der Does-Van Den Berg. In vitro cellular drug resistance and prognosis in childhood acute lymphoblastic leukemia. Blood 1997, 90:2723–2729

    PubMed  CAS  Google Scholar 

  27. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Van der Does-van den Berg A, Veerman AJP. Prednisolone in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other anticancer agents. Blood 1998, 92:259–266

    PubMed  CAS  Google Scholar 

  28. Pieters R, Den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJL, Van Wering ER, veerman AJP. In vitro drug resistance testing in infant acute lymphoblastic leukemia cells — implications for treatment. Leukemia 1998, 12:1344–1348

    Article  PubMed  CAS  Google Scholar 

  29. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leukemia & Lymphoma 1995, 19:407–417

    Article  CAS  Google Scholar 

  30. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 1995, 85:751–756

    PubMed  CAS  Google Scholar 

  31. Dörffel W, Hartmann R, Schober S, Veerman AJP, Pieters R, Klumper E, Henze G. Drug resistance testing as a basis for tailored therapy in children with refractory or relapsed acute lymphoblastic leukemia. In: Kaspers et al. (eds). Drug Resistance in Leukemia and Lymphoma I. Harwood, 1993:353–357

    Google Scholar 

  32. Klumper E, Pieters R, Loonen AH, Huismans DR, Veerman AJP. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer 1995, 71:1188–1193

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology/Oncology, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

    G. J. L. Kaspers, Ch. M. Zwaan, R. Pieters & A. J. P. Veerman

Authors
  1. G. J. L. Kaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ch. M. Zwaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Pieters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. J. P. Veerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    G. J. L. Kaspers , R. Pieters  & A. J. P. Veerman ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kaspers, G.J.L., Zwaan, C.M., Pieters, R., Veerman, A.J.P. (1999). Cellular Drug Resistance in Childhood Acute Myeloid Leukemia. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_44

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4811-9_44

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7180-9

  • Online ISBN: 978-1-4615-4811-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation